humalog kwikpen 200 uml
eli lilly israel ltd, israel - insulin lispro - solution for injection - insulin lispro 200 u/ml - insulin lispro - for the treatment of adults with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. humalog kwikpen 200 units/ml is also indicated for the initial stabilisation of diabetes mellitus.
humulin r
eli lilly israel ltd, israel - insulin (human) - solution for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
humulin 7030
eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
humalog mix 50
eli lilly israel ltd - insulin lispro; insulin lispro protamine - suspension for injection - insulin lispro 50 %; insulin lispro protamine 50 % - insulin lispro - insulin lispro - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
humulin n
eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
humulin 30/70
eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus
humulin nph
eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus
alimta 500 mg
eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
alimta 500 mg
eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
alimta 100 mg
eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 100 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.